Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

View Latest Updates Visitor Restrictions
Explore URMC
menu

Lisa A. Beck, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-7546

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Research Labs

Visit Lab Website

Locations

40 Celebration Dr
College Town
Rochester, NY 14620-2664

Dermatology: (585) 275-7546

Faculty Appointments

Patient Care Setting

Dermatology

Biography

Dr. Beck brings more than 20 years' experience to the treatment of atopic dermatitis and eczema. She is currently involved in an NIH-funded study to determine why certain patients are susceptible to the herpes simplex and Staphylococcus aureus viruses. Dr. Beck received her undergraduate degree from Mount Holyoke College and her medical degree from the State University of New York at Stony Brook.

Research

Dr. Beck's research interests are in three interrelated areas. First, we are interested in characterizing the epithelial tight junction defects at the molecular level in atopic dermatitis, the most common inflammatory skin disease in man. Numerous projects radiate from that central theme and include – 1) how do these defects differ in other inflammatory skin diseases such as chronic urticaria, psoriasis, CTCL, 2) what effects do various pharmacologic agents have on TJ function and structure, 3) can protease containing allergens or microbes affect TJ function and if so how. A second area of focus is evaluating the magnitude and character of the microbial responsiveness of keratinocytes (cutaneous epithelial cells) from atopic dermatitis subjects compared to nonatopic healthy controls. When differences are noted we are trying to determine the basis for these differences and believe this line of inquiry may explain AD subjects' susceptibility to colonization and infection with numerous bacteria, viruses and even yeast. Our third area has been to understand why there is such a paucity of tissue neutrophils in lesions from subjects with atopic dermatitis. These studies are not as advanced but suggest that there are phenotypic differences in AD neutrophils' responsiveness to the potent chemoattractant, IL-8 (CXCL8) compared to nonatopic controls.

Credentials

Education

1985
MD | Stony Brook University

Post-doctoral Training & Residency

07/01/1987 - 07/31/1990
Residency in Dermatology at Duke University Medical Center

07/01/1986 - 07/31/1987
Residency in Internal Medicine at University of Rochester Medical Center

06/27/1985 - 07/31/1986
Internship in Internal Medicine at University of Rochester Medical Center

VIEW ALL expand_more

Awards

2008
Dermatology Faculty Teaching Award
Sponsor: University of Rochester Medical Center

2007
Mentor for NEASE Skin Research Grant Recipient
Sponsor: NEASE

2007
Mentor for AAAAI Summer Research Grant Recipient
Sponsor: AAAAI

2006
Mentor for Astellas Skin Research Grant Recipient
Sponsor: Astellas

2005
Mentor for Fujisawa AAAAI Research Grant Recipient
Sponsor: Fujisawa

1997
Mentor for Howard Hughes Summer Fellowship Recipient
Sponsor: Howard Hughes

1994
Physician-Scientist Award
Sponsor: National Institute of Health

1994
Research Award
Sponsor: Dermatology Foundation

1992
Teaching Appreciation Award
Sponsor: Johns Hopkins University
Location: Dermatology Department

1992
Internal Medicine Teaching Award
Sponsor: Francis Scott Key Medical Center

VIEW ALL expand_more

Clinical Trials

A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS

Lead Researcher: Lisa A Beck

B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken orally once daily (QD) will be identified and randomized in a double-blind manner to receive 200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible patients will have the option to enter a long-term extension study after completing the initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.

View Study Details

Patents

Patent Title: System and Method for Studying Epidermis Samples Ex Vivo
Patent #: 8,993,257
Issue Date: Mar 31, 2015
Country: United States
Invented By: Lisa A Beck, Anna De Benedetto

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: ZL 201480052086.0
Issue Date: Jun 02, 2020
Country: China, People's Republic of
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin L Miller

Patent Title: Designed Peptides for Tight Junction Barrier Modulation
Patent #: 9,757,428
Issue Date: Sep 12, 2017
Country: United States
Invented By: Elizabeth A Anderson, Lisa A Beck, Anna De Benedetto, Benjamin L Miller

VIEW ALL expand_more

Publications

Journal Articles

11/6/2019
Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, Blauvelt A, Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A. "Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial." JAMA dermatology.. 2019 Nov 6; Epub 2019 Nov 06.

11/1/2019
Alexander H, Paller AS, Traidl-Hoffmann C, Beck LA, De Benedetto A, Dhar S, Girolomoni G, Irvine AD, Spuls P, Su J, Thyssen JP, Vestergaard C, Werfel T, Wollenberg A, Deleuran M, Flohr C. "The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group." The British journal of dermatology.. 2019 Nov 1; Epub 2019 Nov 01.

9/2019
Matson CC, Beck LA, Rajasekaran SK. "Using Language That Reflects Who Is the Center of Our Care." Academic medicine : journal of the Association of American Medical Colleges.. 2019 Sep 0; 94(9):1400.

Books & Chapters

2008
Chapter Title: Update on the Managment of Atopic Dermatitis
Book Title: Allergy Frontiers: Epigenetics to Future Perspectives
Author List: Ibrahim SF, DeBenedetto A, Beck LA
Edited By: Pawankar R, Holgate S, Rosenwasser L
Published By: Springer 2008 in Tokyo, Japan

2007
Chapter Title: Regulation of the Production and Activation of Eosinophils and Neutrophils
Book Title: Dermatology in General Medicine
Author List: Beck LA, Loveless J, Holland S
Edited By: Freedberg I, Katz S, Wolff K, Eisen A, Austen KF and Goldsmith L
Published By: McGraw-Hill Co. 2007 in New York

2004
Chapter Title: Dermatitis
Book Title: Current Therapy in Allergy, Immunology and Rheumatology
Author List: Beck LA
Edited By: Lichtenstein LM, Busse WW and Geha RS
Published By: Mosby Yearbook Inc. 2004 in St. Louis

VIEW ALL PUBLICATIONS